Replicable Antigen Library for CTL Response Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine development for infectious diseases and cancer is hindered by the inability to effectively screen and predict which antigens will be immunogenic, leading to low success rates in vaccine programs, especially for intracellular pathogens where the humoral immune response is ineffective.
Innovation Solution
A replicable library of discrete members, each containing a cell or virus with a polynucleotide encoding a portion of a pathogenic organism's genome, linked to a promoter, allowing for the identification of immunogenic polypeptides through interaction with CTL cells, and the use of specific polypeptides like CT788 for vaccine composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine development methods are used without systematic antigen screening, then the development process is simpler and faster to initiate, but the success rate is low due to inability to predict effective antigens
Solution Approach 1:
The patent segments the pathogen's proteome into individual polypeptide components, creating a library where each member expresses a single polypeptide from the pathogen genome. This segmentation allows systematic screening of each antigen component separately, enabling identification of effective antigens without overwhelming complexity.
Solution Approach 2:
The patent performs preliminary action by creating a comprehensive library of pathogen polypeptides before vaccine development. The library is constructed in advance with all possible antigen candidates, allowing researchers to pre-screen and identify effective antigens before committing to full vaccine development programs.
2Reliability
If comprehensive antigen screening is performed to identify effective antigens, then vaccine effectiveness improves, but the time and resources required increase significantly
Solution Approach 1:
The patent employs self-service by using the immune system itself to screen and identify effective antigens. CTL cells from immunized animals automatically recognize and bind to the polypeptides in the library, performing the screening function without requiring complex external analytical methods. This biological self-service accelerates antigen identification.
Solution Approach 2:
The patent changes the parameter of antigen presentation by expressing pathogen polypeptides in heterologous host cells (e.g., E. coli, insect cells, mammalian cells). This parameter change allows the antigens to be produced in a controlled, scalable manner, reducing the time and resources needed for screening while maintaining immunogenicity.
3Reliability
If focus is placed on humoral immune response for intracellular pathogens, then antibody production is enhanced, but protective immunity is ineffective because intracellular pathogens are sequestered within host cells
Solution Approach 1:
The patent inverts the traditional approach by focusing on cell-mediated immunity (CTL response) instead of humoral immunity for intracellular pathogens. Rather than trying to enhance antibody production against hidden pathogens, the patent stimulates CTL cells to directly recognize and kill infected host cells, reversing the conventional strategy and achieving effective protection against intracellular pathogens.
Data Source
AI summary
Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, CT788, which induces T-cell activation during a Chlamydia infection.